{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:51:36Z","timestamp":1776253896652,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05585-3","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:04:35Z","timestamp":1773025475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The novel anticoagulant dabigatran versus enoxaparin for thromboprophylaxis following total hip replacement: a meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Junwu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"5585_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-025-03635-2","author":"C Takeda","year":"2025","unstructured":"Takeda C, Yamashita Y, Masui K, et al. Clinical characteristics, management strategies, and outcomes in patients with preoperative venous thromboembolism who underwent surgery: survey data from 2020 to 2022 by the Japanese Society of Anesthesiologists. J Anesth. 2025. https:\/\/doi.org\/10.1007\/s00540-025-03635-2.","journal-title":"J Anesth"},{"issue":"4","key":"5585_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1272\/jnms.JNMS.2021_88-418","volume":"88","author":"T Majima","year":"2021","unstructured":"Majima T, Oshima Y. Venous thromboembolism in major orthopedic surgery. J Nippon Med Sch. 2021;88(4):268\u201372.","journal-title":"J Nippon Med Sch"},{"issue":"4","key":"5585_CR3","first-page":"e25.00235","volume":"10","author":"SC Woller","year":"2025","unstructured":"Woller SC, Stevens SM, Wylie JD, et al. Standardized thromboembolism prophylaxis in orthopedic patients to prevent venous thromboembolism study: a novel prospectively validated electronic risk stratification tool for elective hip and knee joint replacement patients. JB JS Open Access. 2025;10(4):e25.00235.","journal-title":"JB JS Open Access."},{"issue":"8","key":"5585_CR4","doi-asserted-by":"publisher","first-page":"111650","DOI":"10.1016\/j.injury.2024.111650","volume":"55","author":"FG Ghazi","year":"2024","unstructured":"Ghazi FG, Schenker ML, Smith RN, Spencer CC, Mlaver E. Patient-reported barriers for adherence to prophylactic enoxaparin after orthopedic trauma surgery. Injury. 2024;55(8):111650.","journal-title":"Injury."},{"issue":"6 Suppl","key":"5585_CR5","doi-asserted-by":"publisher","first-page":"381S","DOI":"10.1378\/chest.08-0656","volume":"133","author":"WH Geerts","year":"2008","unstructured":"Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S-453S.","journal-title":"Chest"},{"key":"5585_CR6","unstructured":"Venous Thromboembolism. Reducing the risk of venous Thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing sur gery. Published by: National Collaborating Centre for Acute Care at The Royal College of Surgeons of Eng land, 35\u201343 Lincoln\u2019s Inn Fields, London, WC2A 3PE. Available at:\u00a0http:\/\/www.rcseng.ac.uk\/surgical_research_units\/nccac\/guidelines\/venous_thrombo_guideline.html."},{"issue":"2","key":"5585_CR7","first-page":"e79772","volume":"17","author":"U Asif","year":"2025","unstructured":"Asif U, Ghani U, Zia SMR, et al. Venous thromboembolism prophylaxis compliance in orthopedic patients with cardiac risk factors. Cureus. 2025;17(2):e79772.","journal-title":"Cureus"},{"issue":"1","key":"5585_CR8","doi-asserted-by":"publisher","first-page":"2503697","DOI":"10.1080\/21548331.2025.2503697","volume":"53","author":"B TeferiMekonen","year":"2025","unstructured":"TeferiMekonen B, ShibabawMolla T, FentahunBekalu A, et al. Venous thromboembolism prevention practice and associated factors among orthopedic surgical patients in Ethiopia: a cross-sectional study. Hosp Pract (1995). 2025;53(1):2503697.","journal-title":"Hosp Pract (1995)"},{"issue":"10","key":"5585_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/jpm15100490","volume":"15","author":"A Nasiri","year":"2025","unstructured":"Nasiri A, Alshammari M, Alqahtani R, et al. Next-generation anticoagulants: precision strategies for patient-centered thromboprophylaxis. J Pers Med. 2025;15(10):490.","journal-title":"J Pers Med"},{"issue":"7","key":"5585_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/europace\/eut423","volume":"16","author":"J Kosiuk","year":"2014","unstructured":"Kosiuk J, Koutalas E, Doering M, et al. Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace. 2014;16(7):1028\u201332.","journal-title":"Europace"},{"issue":"10","key":"5585_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2165\/11313800-000000000-00000","volume":"27","author":"L McCullagh","year":"2009","unstructured":"McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics. 2009;27(10):829\u201346.","journal-title":"Pharmacoeconomics."},{"key":"5585_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-1-0716-1566-9_4","volume":"2345","author":"D Langan","year":"2022","unstructured":"Langan D. Assessing heterogeneity in random-effects meta-analysis. Methods Mol Biol. 2022;2345:67\u201389.","journal-title":"Methods Mol Biol"},{"issue":"9","key":"5585_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"5585_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"issue":"1","key":"5585_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","volume":"3","author":"BI Eriksson","year":"2005","unstructured":"Eriksson BI, Dahl OE, B\u00fcller HR, Hettiarachchi R, Rosencher N, Bravo M-L, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103\u201311.","journal-title":"J Thromb Haemost"},{"issue":"9591","key":"5585_CR16","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","volume":"370","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Dahl OE, Rosencher N, Kurth AA, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949\u201356.","journal-title":"Lancet."},{"issue":"4","key":"5585_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1160\/TH10-10-0679","volume":"105","author":"BI Eriksson","year":"2011","unstructured":"Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4):721\u20139.","journal-title":"Thromb Haemost"},{"issue":"4","key":"5585_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00402-014-1933-8","volume":"134","author":"C Gomb\u00e1r","year":"2014","unstructured":"Gomb\u00e1r C, Horvath G, G\u00e1lity H, Sis\u00e1k K, T\u00f3th K. Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty. Arch Orthop Trauma Surg. 2014;134(4):449\u201357.","journal-title":"Arch Orthop Trauma Surg"},{"issue":"1","key":"5585_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1160\/TH08-07-0493","volume":"101","author":"SE Wolowacz","year":"2009","unstructured":"Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009;101(1):77\u201385.","journal-title":"Thromb Haemost."},{"issue":"6","key":"5585_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/THC-140859","volume":"22","author":"P Mommsen","year":"2014","unstructured":"Mommsen P, Doering M, R\u00f6hrs E, Egidy C, Gehrke T, Krettek C, et al. Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty. Technol Health Care. 2014;22(6):901\u20138.","journal-title":"Technol Health Care."},{"issue":"11","key":"5585_CR21","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.arth.2020.06.032","volume":"35","author":"AJ Highcock","year":"2020","unstructured":"Highcock AJ, As-Sultany M, Finley R, Donnachie NJ. A Prospective cohort comparative study of rivaroxaban, dabigatran, and Apixaban oral thromboprophylaxis in 2431 hip and knee arthroplasty patients: primary efficacy outcomes and safety profile. J Arthroplasty. 2020;35(11):3093\u20138.","journal-title":"J Arthroplasty"},{"issue":"1","key":"5585_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/TA.0000000000004331","volume":"97","author":"AJ Kobzeva-Herzog","year":"2024","unstructured":"Kobzeva-Herzog AJ, Smith SM, Counihan DR, et al. Timing of venous thromboembolism prophylaxis initiation and complications in polytrauma patients with high-risk bleeding orthopedic interventions: a nationwide analysis. J Trauma Acute Care Surg. 2024;97(1):96\u2013104.","journal-title":"J Trauma Acute Care Surg."},{"issue":"23","key":"5585_CR23","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.2174\/1381612826666200420150517","volume":"26","author":"PE Papakonstantinou","year":"2020","unstructured":"Papakonstantinou PE, Tsioufis C, Konstantinidis D, Iliakis P, Leontsinis I, Tousoulis D. Anticoagulation in deep venous thrombosis: current trends in the era of non- Vitamin K antagonists oral anticoagulants. Curr Pharm Des. 2020;26(23):2692\u2013702.","journal-title":"Curr Pharm Des."},{"issue":"24","key":"5585_CR24","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342\u201352.","journal-title":"N Engl J Med."},{"issue":"1","key":"5585_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74\u201381.","journal-title":"Drug Metab Dispos."},{"issue":"10","key":"5585_CR26","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484\u20138.","journal-title":"Blood."},{"issue":"26","key":"5585_CR27","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499\u2013510.","journal-title":"N Engl J Med."},{"issue":"3","key":"5585_CR28","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","volume":"136","author":"F Posch","year":"2015","unstructured":"Posch F, K\u00f6nigsbr\u00fcgge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136(3):582\u20139.","journal-title":"Thromb Res"},{"issue":"10","key":"5585_CR29","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","volume":"17","author":"D Farge","year":"2016","unstructured":"Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452\u201366.","journal-title":"Lancet Oncol"},{"issue":"8","key":"5585_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"5585_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720\u20138.","journal-title":"N Engl J Med."},{"issue":"11","key":"5585_CR32","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.62347\/VUAI5958","volume":"16","author":"Lu Qiuyu Li","year":"2024","unstructured":"Qiuyu Li Lu, Liu WY, Zhu Z, Hong Xu. Efficacy and safety of safflower yellow combined with low molecular weight heparin in preventing deep vein thrombosis after orthopedic surgery: a systematic review and meta-analysis. Am J Transl Res. 2024;16(11):6626\u201335.","journal-title":"Am J Transl Res"},{"issue":"3","key":"5585_CR33","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/jeo2.70010","volume":"11","author":"FA Syed","year":"2024","unstructured":"Syed FA, Amin H, Benjamin B, Hendrix M, Savaridas T. Comparative efficacy of aspirin versus direct oral anticoagulants for venous thromboembolism prophylaxis following primary total hip arthroplasty or total knee arthroplasty: a systematic review and meta-analysis of randomised controlled trials. J Exp Orthop. 2024;11(3):e70010.","journal-title":"J Exp Orthop"},{"issue":"9","key":"5585_CR34","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.arth.2025.03.072","volume":"40","author":"SN Chokshi","year":"2025","unstructured":"Chokshi SN, Gay SS, Barimani B, Somerson JS. Effects and complications of apixaban versus aspirin for venous thromboembolism prophylaxis after total hip or knee arthroplasty. J Arthroplasty. 2025;40(9):2387\u201392.","journal-title":"J Arthroplasty"},{"issue":"7","key":"5585_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s11239-024-03015-9","volume":"57","author":"MJ Smeets","year":"2024","unstructured":"Smeets MJ, Kristiansen EB, Nemeth B, Huisman MV, Cannegieter SC, Pedersen AB. Risks of major bleeding and venous thromboembolism in patients undergoing total hip or total knee arthroplasty using therapeutic dosages of DOACs. J Thromb Thrombolysis. 2024;57(7):1249\u201355.","journal-title":"J Thromb Thrombolysis."}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05585-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05585-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05585-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:57:56Z","timestamp":1776250676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05585-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5585"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05585-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval or board review approval and consent to participate were not required for this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}